Empagliflozin improves renal ischemia–reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK–OPA1 pathway promotion
Abstract Background Renal ischemia–reperfusion injury (IRI) is one reason for renal transplantation failure. Recent studies have shown that mitochondrial dynamics is closely related to IRI, and that inhibition or reversal of mitochondrial division protects organs against IRI. Optic atrophy protein 1...
Main Authors: | Wenbo Yang, Xiaoli Li, Liujie He, Shuyang Zhu, Shicong Lai, Xiaopeng Zhang, Zixiong Huang, Biyue Yu, Chunping Cui, Qiang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | Cellular & Molecular Biology Letters |
Subjects: | |
Online Access: | https://doi.org/10.1186/s11658-023-00457-6 |
Similar Items
-
Empagliflozin targets Mfn1 and Opa1 to attenuate microglia-mediated neuroinflammation in retinal ischemia and reperfusion injury
by: Zhenlan Yang, et al.
Published: (2023-12-01) -
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis
by: Rongjun Zou, et al.
Published: (2022-06-01) -
Does Disruption of Optic Atrophy-1 (OPA1) Contribute to Cell Death in HL-1 Cardiomyocytes Subjected to Lethal Ischemia-Reperfusion Injury?
by: Andrew R. Kulek, et al.
Published: (2022-09-01) -
Empagliflozin-loaded nanomicelles responsive to reactive oxygen species for renal ischemia/reperfusion injury protection
by: Cheng Jianjun, et al.
Published: (2024-04-01) -
Empagliflozin: a potential anticancer drug
by: Wenwen Wu, et al.
Published: (2023-07-01)